Chondrosarcoma Pharmaceutical and Healthcare Pipeline Review H2

Summary

Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.

 

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2530984-chondrosarcoma-pipeline-review-h2-2017       

 

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

 

Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)

 

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 

Table of Content: Key Points

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Chondrosarcoma - Overview 7

Chondrosarcoma - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Chondrosarcoma - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Chondrosarcoma - Companies Involved in Therapeutics Development 21

Agios Pharmaceuticals Inc 21

Celgene Corp 21

Daiichi Sankyo Co Ltd 22

Epizyme Inc 22

Horizon Pharma Plc 23

Karyopharm Therapeutics Inc 23

Merck & Co Inc 24

Nektar Therapeutics 24

Novartis AG 25

Ono Pharmaceutical Co Ltd 25

Pfizer Inc 26

…Continued                            

 

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2530984-chondrosarcoma-pipeline-review-h2-2017

                                         

Contact Info:                                                         

NORAH TRENT                                                      

[email protected]             

Ph: +1-646-845-9349 (US)                

Ph: +44 208 133 9349 (UK)                                                   

                                                               

Get in touch:                                                         

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports                                                                  

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts